- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.01. | Aquaporin A/S: Last day of trading in shares with pre-emptive rights in connection with rights issue | 300 | PR Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR... ► Artikel lesen | |
| 02.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.01.2026 | 250 | Xetra Newsboard | Das Instrument 00B DK0061555109 AQUAPORIN A/S DK 1 EQUITY wird cum Kapitalmassnahme gehandelt am 02.01.2026 und ex Kapitalmassnahme am 05.01.2026 The instrument 00B DK0061555109 AQUAPORIN A/S DK 1 EQUITY... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S - rights issue, admission to trading and official listing of subscription rights | 202 | GlobeNewswire | Subscription rights in Aquaporin A/S will be admitted to trading and official listing on Nasdaq Copenhagen as of 5 January 2026. As of the same date, ISIN DK0061555109 (AQP) will be traded excl.... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S: Aquaporin updates on strategic review and sets mid-and long-term financial targets | 243 | PR Newswire | Company announcementNo. 21/2025Inside informationAquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694KONGENS LYNGBY, Denmark, Dec. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S: Aquaporin initiates rights issue | 283 | PR Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S: Aquaporin updates on strategic review and sets mid-and long-term financial targets | 314 | PR Newswire | Company announcementNo. 21/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 19.12.25 | AQUAPORIN A/S: Aquaporin updates on strategic review and sets mid- and long-term financial targets | 2 | Cision News | ||
| AQUAPORIN Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | Business transacted at the extraordinary general meeting of Aquaporin A/S | 290 | PR Newswire | Company announcementNo. 20/2025Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany reg. no.: DK28315694KONGENS LYNGBY, Denmark, Dec. 1, 2025 /PRNewswire/ -- Aquaporin A/S... ► Artikel lesen | |
| 01.12.25 | Aquaporin A/S: Business transacted at the extraordinary general meeting of Aquaporin A/S | 126 | GlobeNewswire (Europe) | Company announcement
No. 20/2025
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company reg. no.: DK28315694
Kongens Lyngby, Denmark, December 1, 2025 - Aquaporin A/S ("Aquaporin"... ► Artikel lesen | |
| 13.11.25 | Aquaporin A/S: Aquaporin Q3 2025 Trading Statement | 209 | PR Newswire | Company announcement
No. 19/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 07.11.25 | Aquaporin A/S: Notice to convene an extraordinary general meeting | 402 | PR Newswire | Company announcement
No. 18/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 07.11.25 | Aquaporin A/S: Update on strategic review and intention to strengthen financial position | 348 | PR Newswire |
Company announcement
No. 17/2025Inside information
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS... ► Artikel lesen | |
| 21.08.25 | Aquaporin A/S: Aquaporin announces results for first half 2025 | 381 | PR Newswire | Company announcement No. 16/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngby aquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug. 21, 2025 /PRNewswire/... ► Artikel lesen | |
| 13.08.25 | AQUAPORIN A/S: Aquaporin to host half-year 2025 results webcast on August 21 | 3 | Cision News | ||
| 12.08.25 | Aquaporin Cuts FY Revenue Guidance, Initiates Strategic Review | 1 | RTTNews | ||
| 11.08.25 | Aquaporin A/S: Aquaporin lowers revenue guidance for 2025, but maintains EBITDA guidance, and initiates strategic review | 1.132 | PR Newswire | Company announcementNo. 15/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug.... ► Artikel lesen | |
| 05.08.25 | Aquaporin A/S: Aquaporin successfully achieves up to 20% energy savings at Kranji NEWater Factory | 366 | PR Newswire | KONGENS LYNGBY, Denmark, Aug. 5, 2025 /PRNewswire/ -- Aquaporin has successfully completed the Living Lab Project to develop the world's first biomimetic low-energy Aquaporin Inside® CLEAR... ► Artikel lesen | |
| 12.06.25 | Aquaporin A/S: Aquaporin appoints Chief Executive Officer | 475 | PR Newswire | Company announcementNo. 09/2025
Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark... ► Artikel lesen | |
| 21.05.25 | Aquaporin A/S: Aquaporin Q1 2025 Trading Statement - maintains full-year financial guidance for 2025 | 376 | PR Newswire | Company announcementNo. 08/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark , May 21, 2025 /PRNewswire/... ► Artikel lesen | |
| 11.04.25 | Aquaporin A/S - Admittance to trading and official listing of new shares due to exercise of warrants | 223 | GlobeNewswire | The share capital of Aquaporin A/S has been increased. The admittance of trading and official listing of new shares will take effect as per 14 April 2025 in the ISIN below.
ISIN:
DK0061555109
Name:
Aquaporin
Volume... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIODESIX | 7,870 | +44,14 % | Biodesix, Inc.: Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) | Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 34,835 | +26,44 % | Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition | Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. Biologics Licensing Application (BLA)... ► Artikel lesen | |
| QIAGEN | 40,935 | -0,72 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,310 | -12,04 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,855 | +4,18 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 10,620 | +18,79 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| BIONTECH | 86,10 | +0,23 % | BioNTech-Aktie: Ein guter Kauf für 2026? | Seit Anfang Dezember 2025 tritt die BioNTech-Aktie bei Kursen um die 96 US$ auf der Stelle. Auch zum Jahresstart zeigt sie wenig Bewegung. Sehen Anleger hier keine guten Investmentchancen für 2026?... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 17,320 | -6,38 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 55,00 | +1,48 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| ABIVAX | 103,60 | +4,86 % | Abivax: NBC-Volltreffer explodiert erneut - wird die Übernahme jetzt besiegelt? | Der US-Pharmakonzern Eli Lilly prüft eine der größten Übernahmen im europäischen Biotechnologiesektor: Rund 15 Milliarden Euro könnte demnach der Kauf der französischen Biotech-Gesellschaft Abivax kosten.... ► Artikel lesen | |
| EVOTEC | 6,476 | +3,02 % | Evotec Aktie: Das große Comeback im Jahr 2026? | Nächster Anlauf der Evotec Aktie auf große charttechnische Kaufsignale - bisher misslangen diese Ausbruchsversuche. Nachdem die Biotech-Aktie in den letzten Tagen zunächst an der Unterstützung bei 5... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,540 | -5,95 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| ALUMIS | 20,310 | +3,83 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 275,15 | -4,61 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 7,460 | -29,22 % | Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy | LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants... ► Artikel lesen |
AQUAPORIN A/S gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -6,25 % bei einem Aktienkurs von 0,135 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AQUAPORIN A/S finden Sie auf Wallstreet Online.